OPEN END TURBO OHNE STOP-LOSS - NOVO-NORDISK B | Delayed Börse Stuttgart 02:10:22 2024-07-05 am EDT | ||
| 21.65 EUR | +0.70% |
|
| Current month | -5.87% | ||
| 1 month | +3.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 21.65 | +0.70% |
| 24-07-04 | 21.5 | -3.33% |
| 24-07-03 | 22.24 | -3.14% |
| 24-07-02 | 22.96 | +1.59% |
| 24-07-01 | 22.6 | -1.05% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 02:10 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Lang & Schwarz |
| WKN | LS5FE9 |
| ISIN | DE000LS5FE99 |
| Date issued | 2019-06-06 |
| Strike | 21.1 € |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.11 € |
|---|---|
| Lowest since issue | 0.32 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Certificates
- Certificat
